6,7,4'-Trihydroxyisoflavone

SKU: orb1219410

Description

6,7,4'-Trihydroxyisoflavone, is a novel inhibitor of PKCα in suppressing solar UV-induced matrix metalloproteinase 1, which has antioxidant, and anti-cancer activities.Molecular studies showed that 6,7,4'-THIF significantly inhibited acetylcholinesterase and thiobarbituric acid reactive substance (TBARS) activities in the hippocampus of scopolamine-induced mice.In addition, immunohistochemistry and Western blot results revealed that 6,7,4'-THIF significantly increased brain-derived neurotrophic factor (BDNF) and phosphor cAMP response element binding (CREB) in the hippocampus of mice. A single administration of 6,7,4'-THIF significantly improved scopolamine-induced cognitive dysfunction in these in vivo tests. Moreover, treatment with 6,7,4'-THIF alone enhanced learning and memory performance in the same behavioral tests. 6,7,4'-THIF improves cognitive dysfunction induced by scopolamine and enhances learning and memory by activation of the cholinergic system and the p-CREB/BDNF signaling pathway in mice.

Key Properties

• CAS Number: 17817-31-1
• MW: 270.2
• Purity: >98% (HPLC)
• Formula: C₁₅H₁₀O₅
• SMILES: O=C1C(C2=CC=C(O)C=C2)=COC3=CC(O)=C(O)C=C13
• Target: PKC
• Solubility: DMSO:125 mg/mL (462.55 mM; Need ultrasonic)

Bioactivity

• In Vivo:
  Desmethylglycitein (4', 6, 7-Trihydroxyisoflavone) (intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days) suppresses tumor development in mice and serves as an effective anticancer treatment with the potential to inhibit or delay the tumorigenicity of HCT-116 cells in an In vivo system. Animal model: Female athymic nude mice subcutaneously injected with HCT-116 cells. Dosage: 5 or 25 mg/kg. Administration: Intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days. Result: Decreased tumor growth, volume and weight of HCT-116 xenografts.
  Read more...
• In Vitro:
  Desmethylglycitein (4', 6, 7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppessesanchorage-dependent growth of HCT-116 and DLD1 cells in a dose- and time-dependent manner without cytotoxicity. Desmethylglycitein (4', 6, 7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppresses CDK1 activity in a dose-dependent manner andinhibits CDK2 activity in HCT-116 cells. Desmethylglycitein (4', 6, 7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) induces cell cycle arrest at the S and G2/M phases, the percentage of cells in S phase is higher in the 100 μM 6, 7, 4′-THIF-treated group, and the same pattern is observed in G2/M phase (29.5% versus 19.1% ). Cell Viability Assay Cell line: HCT-116 cells. Concentration: 0, 12.5, 25, 50 or 100 μM Incubation time: 24, 48 or 72 hours. Result: Inhibited anchorage-dependent and -independent growth of HCT-116 cells. Western blot analysis. Cell line: HCT-116 and DLD1 cells. Concentration: 0, 25, 50 or 100 μM. Incubation time: 48 hours. Result: Inhibited CDK1, CDK2 expression. Cell Cycle Analysis Cell line: HCT-116 cells. Concentration: 0, 25, 50 or 100 μM. Incubation time: 24, 48 or 72 hours. Result: Induces cell cycle arrest of HCT-116 cells at S and G2/M phases.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

PKC